UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Circadian dependence of the acute immune response to myocardial infarction

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Influence of mental stress and environmental toxins on circadian clocks: Implications for redox regulation of the heart and cardioprotection

British journal of pharmacology, 2020-12, Vol.177 (23), p.5393-5412

2020

Volltextzugriff (PDF)

Redox Regulatory Changes of Circadian Rhythm by the Environmental Risk Factors Traffic Noise and Air Pollution

Antioxidants & redox signaling, 2022-10, Vol.37 (10-12), p.679-703

2022

Volltextzugriff (PDF)

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Annals of the rheumatic diseases, 2014-01, Vol.73 (1), p.183-190

2014

Volltextzugriff (PDF)

Positive Correlation Between Women’s Status and Intimate Partner Violence Suggests Violence Backlash in Mwanza, Tanzania

Journal of interpersonal violence, 2022-11, Vol.37 (21-22), p.NP20331-NP20360

2022

Volltextzugriff (PDF)

Morphological and ontogenetic stratification of abyssal and hadal Eurythenes gryllus sensu lato (Amphipoda: Lysianassoidea) from the Peru–Chile Trench

Deep-sea research. Part I, Oceanographic research papers, 2016-03, Vol.109, p.91-98

2016

Volltextzugriff (PDF)

Toxicity and efficacy of chronomodulated chemotherapy: a systematic review

The lancet oncology, 2022-03, Vol.23 (3), p.e129-e143

2022

Volltextzugriff (PDF)

Circadian Dependence of the Acute Immune Response to Myocardial Infarction

Frontiers in pharmacology, 2022-05, Vol.13, p.869512-869512

2022

Volltextzugriff (PDF)

Misperception of peer beliefs reinforces inequitable gender norms among Tanzanian men

Evolutionary human sciences, 2024, Vol.6, p.e17-e17, Article e17

2024

Volltextzugriff (PDF)

He for she? Variation and exaggeration in men's support for women's empowerment in northern Tanzania

Evolutionary human sciences, 2021, Vol.3, p.e27-e27, Article e27

2021

Volltextzugriff (PDF)

Making the Connection: Using Concept Mapping to Bring the Basic Sciences to the Diagnosis

Journal of Osteopathic Medicine (Online), 2020-08, Vol.120 (8), p.524-528

2020

Volltextzugriff (PDF)

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

Rheumatology (Oxford, England), 2013-07, Vol.52 (7), p.1313-1322

2013

Volltextzugriff (PDF)

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

Rheumatology (Oxford, England), 2014-03, Vol.53 (3), p.502-511

2014

Volltextzugriff (PDF)

Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study

Arthritis care & research (2010), 2016-04, Vol.68 (4), p.534-543

2016

Volltextzugriff (PDF)

Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study

Cancers, 2022-05, Vol.14 (10), p.2361

2022

Volltextzugriff (PDF)

FRI0002 Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Cynomolgus Monkeys and in Patients with Systemic Lupus Erythematosus

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.420-420

2015

Volltextzugriff (PDF)

Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: Protocol for a Systematic Review

JMIR research protocols, 2020-10, Vol.9 (10), p.e18023-e18023

2020

Volltextzugriff (PDF)

AB0617 Characterization of SLE patients experiencing flares in epratuzumab clinical trials

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.674-674

2013

Volltextzugriff (PDF)

THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A257-A257

2013

Volltextzugriff (PDF)

THU0286 Immunologic Response to Long-Term Epratuzumab Treatment in Sl0008, An Open-Label Long-Term Extension Study in Patients with Moderate-to-Severe Systemic Lupus Erythematosus

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A262-A263

2013

Volltextzugriff (PDF)

AB0633 Epratuzumab-treated SLE patients report improvements in health-related quality of life: Interim results from a us open-label extension study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.675-675

2013

Volltextzugriff (PDF)

Conditional expression of Spry1 in neural crest causes craniofacial and cardiac defects

BMC developmental biology, 2010-05, Vol.10 (1), p.48-48, Article 48

2010

Volltextzugriff (PDF)

THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A259-A259

2013

Volltextzugriff (PDF)

Sexual behaviors and reproductive health outcomes: associations with wife abuse in India

JAMA : the journal of the American Medical Association, 1999-11, Vol.282 (20), p.1967

1999

Volltextzugriff (PDF)

Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus Following Epratuzumab TreatmentResults From A Phase Iib Study And Its Open-Label Extension

Value in health, 2014-05, Vol.17 (3), p.A232-A233

2014

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(31)
Tagungsberichte
(1)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Humans
(9)
Female
(8)
Adult
(7)
Male
(6)
Middle Aged
(5)
Circadian Rhythms
(4)
Lupus Erythematosus, Systemic - Drug Therapy
(4)
Rheumatology
(4)
Risk Factors
(4)
Severity Of Illness Index
(4)
Treatment Outcome
(4)
Women
(4)
Adolescent
(3)
Antibodies, Monoclonal, Humanized - Adverse Effects
(3)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(3)
Circadian Rhythm
(3)
Coronary Artery Disease
(3)
Empowerment
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circadian dependence of the acute immune response to myocardial infarction

Influence of mental stress and environmental toxins on circadian clocks: Implications for redox regulation of the heart and cardioprotection

Redox Regulatory Changes of Circadian Rhythm by the Environmental Risk Factors Traffic Noise and Air Pollution

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Positive Correlation Between Women’s Status and Intimate Partner Violence Suggests Violence Backlash in Mwanza, Tanzania

Morphological and ontogenetic stratification of abyssal and hadal Eurythenes gryllus sensu lato (Amphipoda: Lysianassoidea) from the Peru–Chile Trench

Toxicity and efficacy of chronomodulated chemotherapy: a systematic review

Circadian Dependence of the Acute Immune Response to Myocardial Infarction

Misperception of peer beliefs reinforces inequitable gender norms among Tanzanian men

He for she? Variation and exaggeration in men's support for women's empowerment in northern Tanzania

Making the Connection: Using Concept Mapping to Bring the Basic Sciences to the Diagnosis

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study

Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study

FRI0002 Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Cynomolgus Monkeys and in Patients with Systemic Lupus Erythematosus

Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: Protocol for a Systematic Review

AB0617 Characterization of SLE patients experiencing flares in epratuzumab clinical trials

THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

THU0286 Immunologic Response to Long-Term Epratuzumab Treatment in Sl0008, An Open-Label Long-Term Extension Study in Patients with Moderate-to-Severe Systemic Lupus Erythematosus

AB0633 Epratuzumab-treated SLE patients report improvements in health-related quality of life: Interim results from a us open-label extension study

Conditional expression of Spry1 in neural crest causes craniofacial and cardiac defects

THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

Sexual behaviors and reproductive health outcomes: associations with wife abuse in India

Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus Following Epratuzumab TreatmentResults From A Phase Iib Study And Its Open-Label Extension

Suchergebnisse filtern